---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-060366"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2025-07-01T23:59:59+00:00"
generated_at: "2026-05-18T10:33:48.761021+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Allarity Therapeutics receives Australian patent acceptance for stenoparib DRP companion diagnostic

## Summary
- IP Australia accepted patent application covering 40 claims for DRP companion diagnostic specific to stenoparib.
- Patent to be advertised June 26, 2025; three-month opposition period; grant expected within 20 working days if unopposed.
- Company holds 18 granted drug-specific DRP patents, including 8 in US; European patent for stenoparib DRP previously secured.
- Applications pending in US, Canada, Japan, China, and India.

## SEC filing metadata
- accession: 0001213900-25-060366
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2025-07-01T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390025060366/0001213900-25-060366-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390025060366/ea0247668-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-060366
- JSON: https://secwatch.observer/filing/0001213900-25-060366.json
- Plain text: https://secwatch.observer/filing/0001213900-25-060366.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.